scholarly journals Hepatitis B Virus Belated Reverse Sero-conversion After Hematopoietic Stem Cell Transplantation or Rituximab Chemotherapy

2017 ◽  
Vol 22 (3) ◽  
pp. 132-136
Author(s):  
Tuncer Temel ◽  
Nur Oğuz ◽  
Şafak Meriç Özgenel ◽  
Hava Üsküdar Teke ◽  
Eren Gündüz ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hematopoietic Stem Cell Transplantation ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
B Virus

scholarly journals Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation

2021 ◽  
pp. 178-187
Author(s):  
Mio Tsuruoka ◽  
Jun Inoue ◽  
Yasushi Onishi ◽  
Masashi Ninomiya ◽  
Eiji Kakazu ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hematopoietic Stem Cell Transplantation ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hbv Dna ◽  
Hematopoietic Stem ◽  
B Virus

Reactivation of hepatitis B virus (HBV) is known to occur frequently after hematopoietic stem cell transplantation (HSCT). The reactivation can be prevented by nucleos(t)ide analogue (NA), but it is unclear how long NA should be continued. Here, we report 3 cases of HBV reactivation with discontinuation of NA following the discontinuation of immunosuppressive therapies after HSCT. Three male patients aged 34, 59, and 54 years received allogeneic HSCT (allo-HSCT) for chronic myeloid leukemia, mixed phenotype acute leukemia, and myelodysplastic syndrome, respectively. Before HSCT, 2 patients were positive for hepatitis B surface antigen (HBsAg) and 1 patient was negative for HBsAg and positive for antibodies to hepatitis B core antigen. NA (lamivudine or entecavir) was started at the same time as HSCT and stopped after the discontinuation of immunosuppressive therapies. In all patients, the serum HBV DNA levels were increased after the discontinuation of NAs. Two of the three patients developed severe hepatitis with high levels of HBV DNA (7.5 and 7.4 log IU/mL, respectively). A patient without hepatitis was re-administered NA soon after the HBV DNA started to increase (3.3 log IU/mL). Interestingly, the 2 patients who developed hepatitis cleared HBsAg promptly after the recovery from hepatitis and they could stop NAs without the reversion of HBsAg. It was speculated that transplanted immune cells, which were naïve for HBV, react strongly with HBV antigens that were increased after the NA discontinuation. The discontinuation of NA after allo-HSCT is not recommended generally because strong hepatitis might be induced even after several years.

Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe

1999 ◽  
Vol 31 (2) ◽  
pp. 202-209 ◽  
Author(s):  
Celalettin Üstün ◽  
Ramazan Idilman ◽  
Günhan Gürman ◽  
Muhit Özcan ◽  
Gülen Akyol ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hematopoietic Stem Cell Transplantation ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
B Virus

scholarly journals Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell Transplantation

2009 ◽  
Vol 15 (9) ◽  
pp. 1049-1059 ◽  
Author(s):  
Sarah P. Hammond ◽  
Anne Marie Borchelt ◽  
Chinweike Ukomadu ◽  
Vincent T. Ho ◽  
Lindsey R. Baden ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hematopoietic Stem Cell Transplantation ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Virus Reactivation ◽  
Hematopoietic Stem ◽  
Hepatitis B Virus Reactivation ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document